Eric Baudin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Baudin has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
S. Leboulleux
20 shared publicationsM Schlumberger
13 shared publications- Martin Schlumberger
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris-Sud, Villejuif, France
13 shared publications - Clarisse Dromain
Lausanne University Hospital
11 shared publications A. Berdelou
9 shared publications- Jérôme Bertherat
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
7 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (4) , 262-263
Intérêt de l’iode 131 chez les patients avec métastases à distance de carcinome thyroïdiens différenciés qui fixent l’iode radioactive et le FDG
- 1 September 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (4) , 262-263
Intérêt de l’iode 131 chez les patients avec métastases à distance de carcinome thyroïdiens différenciés qui fixent l’iode radioactive et le FDG
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi137
Genomic profile in pulmonary neuroendocrine tumors (puNETs): the whole-exome sequencing (WES) as a strategic tool
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi137
Genomic profile in pulmonary neuroendocrine tumors (puNETs): the whole-exome sequencing (WES) as a strategic tool
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi136
Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study
Background: Advanced lung/thymus carcinoid is an area of high unmet medical need. In recent phase 3 RADIANT-4 study, everolimus (E) showed progression-free survival (PFS) benefit in patients (pts) with GI/lung NET. Pasireotide LAR (P, somatostatin analog [SSA]), has also shown potential antitumor activity in previous studies in NET. This phase 2 study evaluated efficacy and safety of E, P, and P + E in pts withprogressive carcinoids of lung/thymus.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi136
Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study
Background: Advanced lung/thymus carcinoid is an area of high unmet medical need. In recent phase 3 RADIANT-4 study, everolimus (E) showed progression-free survival (PFS) benefit in patients (pts) with GI/lung NET. Pasireotide LAR (P, somatostatin analog [SSA]), has also shown potential antitumor activity in previous studies in NET. This phase 2 study evaluated efficacy and safety of E, P, and P + E in pts withprogressive carcinoids of lung/thymus.
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 280
Interféron alpha pour le traitement des patients atteints de phéochromocytome/paragangliome métastatique
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 280
Interféron alpha pour le traitement des patients atteints de phéochromocytome/paragangliome métastatique
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 290
Les patients avec un corticosurrénalome de stade IV et une survie prolongée répondent avant 6mois aux thérapies systémiques : une analyse rétrospective du réseau COMETE
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 290
Les patients avec un corticosurrénalome de stade IV et une survie prolongée répondent avant 6mois aux thérapies systémiques : une analyse rétrospective du réseau COMETE
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 258
Mapp-prono : étude européenne rétrospective pronostique des phéochromocytomes et paragangliomes malins
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 258
Mapp-prono : étude européenne rétrospective pronostique des phéochromocytomes et paragangliomes malins
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 257
Les approches lipidomiques et métabolomiques identifient les MAM (mitochondria-associated membranes) comme la cible cellulaire du mitotane
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 257
Les approches lipidomiques et métabolomiques identifient les MAM (mitochondria-associated membranes) comme la cible cellulaire du mitotane
- 1 July 2016
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (7) , 2733-2741
Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer
Background: Anti-angiogenic Tyrosine Kinase Inhibitors (TKI) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity. Objective: to determine the incidence and to investigate the risk factors of hemoptysis in TC patients during TKI treatment. Methods: We analyzed consecutive TC patients treated with TKI in our center between 2005 and 2013 and performed an independent review of CT-scan images for airway invasion assessment. Occurrence of grade 1–2 or grade 3–5 hemoptysis according to CTCAE version 4.03 and risk factors for hemoptysis were investigated. Results: 140 patients (89 males, median age: 52 years) with medullary (56%), differentiated (33%) and poorly differentiated TC (11%) were enrolled. Thyroidectomy±neck dissection was performed in 123 patients and neck/mediastinum external-beam radiotherapy (EBRT) in 41 (32% with therapeutic purpose and 68% with adjuvant purpose). Patients received from 1 to 4 lines of TKI (median 1). Median follow-up was 24 months. Airway invasion was found in 65 (46%) cases. Hemoptysis occurred in 9 patients: grade 1–2 in 7 cases (5%) and grade 3–5 in 2 (1.4%) cases (fatal in one). Hemoptysis was associated with presence of airway invasion [p= 0.04], poorly differentiated pathology [0.03], history of therapeutic EBRT [p= 0.003] and thyroidectomy without neck dissection [p= 0.02]. Conclusion: Airway invasion, poorly differentiated pathology, therapeutic EBRT and thyroidectomy without neck dissection are associated with and increased risk of hemoptysis in TC patients during anti-angiogenic TKI treatment. Further research is needed to confirm this data and to sort out interactions between these risk factors. A careful assessment of airway invasion is mandatory before TKI introduction.
- 1 July 2016
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (7) , 2733-2741
Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer
Background: Anti-angiogenic Tyrosine Kinase Inhibitors (TKI) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity. Objective: to determine the incidence and to investigate the risk factors of hemoptysis in TC patients during TKI treatment. Methods: We analyzed consecutive TC patients treated with TKI in our center between 2005 and 2013 and performed an independent review of CT-scan images for airway invasion assessment. Occurrence of grade 1–2 or grade 3–5 hemoptysis according to CTCAE version 4.03 and risk factors for hemoptysis were investigated. Results: 140 patients (89 males, median age: 52 years) with medullary (56%), differentiated (33%) and poorly differentiated TC (11%) were enrolled. Thyroidectomy±neck dissection was performed in 123 patients and neck/mediastinum external-beam radiotherapy (EBRT) in 41 (32% with therapeutic purpose and 68% with adjuvant purpose). Patients received from 1 to 4 lines of TKI (median 1). Median follow-up was 24 months. Airway invasion was found in 65 (46%) cases. Hemoptysis occurred in 9 patients: grade 1–2 in 7 cases (5%) and grade 3–5 in 2 (1.4%) cases (fatal in one). Hemoptysis was associated with presence of airway invasion [p= 0.04], poorly differentiated pathology [0.03], history of therapeutic EBRT [p= 0.003] and thyroidectomy without neck dissection [p= 0.02]. Conclusion: Airway invasion, poorly differentiated pathology, therapeutic EBRT and thyroidectomy without neck dissection are associated with and increased risk of hemoptysis in TC patients during anti-angiogenic TKI treatment. Further research is needed to confirm this data and to sort out interactions between these risk factors. A careful assessment of airway invasion is mandatory before TKI introduction.